From Targeted Therapy to Drug Resistance Monitoring: The Clinical Auxiliary Value of Tumor Gene Mutation Testing

Positioning in clinical decision support

Tumor gene mutation testing is mainly used in clinical practice to help identify individuals who may benefit from specific targeted therapies and to help refine molecular classification. Test results do not constitute a promise of efficacy, but provide the clinical team with more molecular-level information for comprehensive judgment in combination with imaging, pathology, and laboratory indicators.

From targeted therapy to resistance monitoring

For patients with clearly identified driver gene alterations, test results may indicate whether the corresponding target of a targeted drug is present. If progression occurs during treatment, repeat testing may reveal secondary resistance mutations and help clinicians understand the resistance mechanism. Such dynamic monitoring usually uses liquid biopsy as a supplement to tissue biopsy, but a negative test should not rule out the possibility of tissue-specific mutations or low-frequency clones.

Result interpretation requires awareness of boundaries

Gene alterations are diverse, and not all mutations have clear clinical significance. Reports should distinguish among levels such as "clearly clinically significant," "potentially clinically significant," and "variant of uncertain significance." When interpreting results, clinicians need to consider variant abundance, tumor heterogeneity, and prior treatment background, and avoid making aggressive decisions based on a single gene result alone.

Multidisciplinary collaboration enhances the value of testing

The value of tumor gene mutation testing is often reflected in multidisciplinary discussions involving medical oncology, pathology, molecular diagnostics laboratories, bioinformatics, and pharmacy. By integrating molecular information with clinical phenotypes, the rationality of result utilization can be improved, and unnecessary testing or misunderstanding can be reduced. When communicating with patients, the purpose, limitations, and possible results of testing should be objectively explained, and improper expressions such as "precision cure" should be avoided.

Examples of common application scenarios

In tumor types such as non-small cell lung cancer, colorectal cancer, and thyroid cancer, some guidelines have incorporated specific gene mutation testing into routine molecular evaluation processes. Different tumor types and stages have different requirements for testing timing, sample selection, and reporting. Laboratories should clarify the applicable population and intended use before launching a project.

Future trends and rational outlook

With declining technology costs and accumulating evidence, tumor gene mutation testing is transitioning from single companion diagnostics to more comprehensive molecular profiling. However, before new technologies are introduced into clinical practice, they require sufficient performance confirmation and clinical validation, and quality and applicability should not be ignored because a technology is novel. The industry should focus on standardization, data sharing, and ethical norms to promote the auxiliary value of testing within reasonable boundaries.

Physician-patient communication and informed consent

Before testing, sufficient informed disclosure should be provided, explaining the scope of testing, incidental variants that may be found, and how data will be used. Patients have the right to understand the limitations of testing and to make choices based on that understanding. Standardized communication helps form reasonable expectations and reduce information asymmetry.